Folate immobilized and PEGylated adenovirus for retargeting to tumor cells

Bioconjugate Chemistry

Volumn 17, Issue 3, 2006, Pages 721-727

  Oh, In Kyung ^a   Mok, Hyejung ^a   Park, Tae Gwan ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; GENE THERAPY; IMMUNE SYSTEM;

CELL LINES; FOLATE RECEPTOR; FOLATES; GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN EXPRESSION; IMMUNE RESPONSE; PEGYLATED; PROTEIN GENES; TUMOUR CELLS; VIRAL GENES;

POLYETHYLENE GLYCOLS;

FOLATE RECEPTOR; FOLIC ACID; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 6; MACROGOL;

ADENOVIRUS; ANIMAL CELL; ARTICLE; CELL LINE; CELL STRAIN A549; CELL STRAIN KB; CONJUGATION; CONTROLLED STUDY; CYTOKINE RELEASE; DNA MODIFICATION; DRUG TARGETING; EMBRYO; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MACROPHAGE; MOUSE; NONHUMAN; TUMOR CELL; VIRAL GENE THERAPY;

ADENOVIRIDAE;

EID: 33646907927     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc060030c     Document Type: Article

References (34)

1. Pfeifer, A., and Verma, I. M. (2000) Gene Therapy, promises and problems. Annu. Rev. Genomics Hum. Genet. 2, 117-211.
2. Hunt, K. K., and Vorburger, S. A. (2002) Gene therapy: hurdles and hopes for cancer treatment. Science 297, 415-416.
3. Eto, Y., Gao, J. Q., Sekiguchi, F., Kurachi, S., Katayama, K., Maeda, M., Kawasaki, K., Mizuguchi, H., Hayakawa, T., Tsutsumi, Y., Mayumi, T., and Nakagawa, S. (2005) PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J. Gene Med. 7, 604-612.
4. Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt-Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., and Finberg, R. W. (1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323.
5. Fields, B. N., (1996) Adenoviruses: the viruses and their replication, fields virology, 3rd ed., pp 2111-2148, Lippincott-Raven Publishers, Philadelphia.
6. Engelhardt, J. F., Ye, X., Doranz, B., and Wilson, J. M. (1994) Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. U.S.A. 91, 6196-6200.
7. Yang, Y., and Wilson, J. M. (1995) Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat. Med. 1, 890-893.
8. Dai, Y., Schwarz, E. M., Gu, D., Zhang, W. W., Sarvetnick, N., and Verma, I. M. (1995) Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. U.S.A. 92, 1401-1405.
9. O'Riordan, C. R., Lachapelle, A., Delgado, C., Parkes, V., Wadsworth, S. C., and Smith, A. E. Francis GE. (1999) PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene Ther. 10, 1349-1358.
10. Croyle, M. A., Yu, Q. C., and Wilson, J. M. (2000) Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum. Gene Ther. 11, 1713-1722.
11. Croyle, M. A., Chirmule, N., Zhang, Y., and Wilson, J. M. (2001) "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J. Virol. 75, 4792-4801.
12. Croyle, M. A., Le, H. T., Linse, K. D., Cerullo, V., Toietta, G., Beaudet, A., and Pastore, L. (2005) PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther. 12, 579-587.
13. Croyle, M. A., Callahan, S. M., Auricchio, A., Schumer, G., Linse, K. D., Wilson, J. M., Brunner, L. J., and Kobinger, G. P. (2004) PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J. Virol. 78, 912-921.
14. Jooss, K., Ertl, H. C., and Wilson, J. M. (1998) Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J. Virol. 72, 2945-2954.
15. Yang, Y., Jooss, K. U., Su, Q., Ertl, H. C., and Wilson, J. M. (1996) Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3, 137-144.
16. Yang, Y., and Wilson, J. M. (1995) Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J. Immunol. 155, 2564-2570.
17. Yang, Y., Greenough, K., and Wilson, J. M. (1996) Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther. 3, 412-420.
18. Ross, J. F., Chaudhuri, P. K., and Ratnam, M. (1994) Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73, 2432-2443.
19. Wu, M., Gunning, W., and Ratnam M. (1999) Expression of folate receptor type α in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol. Biomarkers Prev. 8, 775-782.
20. Zhao, X. B., and Lee, R. J. (2004) Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. Adv. Drug. Delivery Rev. 56, 1193-1204.
21. Beale, P., and Clarke, S. (1999) Tomudex: clinical development. Antifolate Drugs in Cancer Chemotherapy, pp 167-181, Humana Press Inc., Totowa, NJ.
22. Konda, S. D., Aref, M., Brechbiel, M., and Wiener, E. C. (2000) Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor: work in progress. Invest. Radiol. 35, 50-57.
23. Yoo, H. S., and Park, T. G. (2004) Folate receptor targeted biodegradable polymeric doxorubicin micelles. J. Controlled Release 96, 273-283.
24. Yoo, H. S., and Park, T. G. (2004) Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J. Controlled Release 100, 247-256.
25. Kim, S. H., Jeong, J. H., Chun, K. W., and Park, T. G., (2005) Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate. Langmuir 21, 8852-8857.
26. Kim, S. H., Jeong, J. H., Cho, K. C., Kim, S. W., and Park, T. G. (2005) Target-specific gene silencing by siRNA plasmid DNA complexed with folate-modified poly(ethylenimme). J. Controlled Release 104, 223-232.
27. Cho, K. C., Kim, S. H., Jeong, J. H., and Park, T. G. (2005) Folate receptor-mediated gene delivery using folate-poly(ethylene glycol)-poly(L- lysine) conjugate. Macromol. Biosci. 5, 512-519.
28. pSilencer adeno 1.0-CMV-Adenoviral siRNA expression vector system-Catalog # 5790, Instruction manual, Ambion, pp 37-39.
29. Curiel, D. T. (1999) Strategies to adapt adenoviral vectors for targeted delivery. Ann. N. Y. Acad. Sci. 886, 158-171.
30. Enjalbal, C., Ribiere, P., Lamaty, F., Yadav-Bhatnagar, N., Martinez, J., and Aubagnac, J. L. (2005) MALDI-TOF MS analysis of soluble PEG based multistep synthetic reaction mixtures with automated detection of reaction failure. J. Am. Soc. Mass Spectrom. 16, 670-678.
31. Mok, H., Palmer, D. J., Ng, P., and Barry, M. A. (2005) Evaluation of poly(ethylene glycol) modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol. Ther. 11, 66-79.
32. Pearce, O. M., Fisher, K. D., Humphries, J., Seymour, L. M., Smith, A., and Davis, B. G. (2005) Glycoviruses: chemical glycosylation retargets adenoviral gene transfer. Angew. Chem., Int. Ed. 44, 1057-1061.
33. Alemany, R., and Curiel, D. T. (2001) CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther. 8, 1347-1353.
34. Medina-Kauwe, L. K. (2003) Endocytosis of adenovirus and adenovirus capsid proteins. Adv. Drug Delivery Rev. 14; 55, 1485-1496.